Recent developments highlight the company’s strategic moves in digital asset acquisitions, telemedicine platform expansion, and regulatory milestones in blockchain-linked security distributions.

• Dogecoin Cash, Inc. announced completion of unit distribution processing and DTC participant allocation in January 2026 [N1].
• The company became among the first U.S. public companies to complete a FINRA-notified blockchain-linked security distribution in January 2026 [N2][N3].
• DOGP moved to nearly double its DOG token holdings through a strategic agreement in December 2025 [N4].
• PrestoDoctor expanded telehealth cannabis evaluations to Connecticut, operating in 19 states nationwide as of September 2025 [N6].
• PrestoDoctor expanded into Michigan ahead of new cannabis tax changes in October 2025 [N5].
• PrestoDoctor began accepting cryptocurrency payments, including Dogecoin, in September 2025 [N7].
• Dogecoin Cash, Inc. announced PrestoDoctor’s expansion into three new markets in August 2025 [N8].

The company’s expansion of the PrestoDoctor telemedicine platform into multiple states, including recent entries into Connecticut and Michigan, demonstrates growth in geographic reach. Acceptance of cryptocurrency payments, including Dogecoin, may attract a broader patient base. Strategic acquisitions of large quantities of Dogecoin Cash tokens through subsidiaries indicate active digital asset management. The asset-light platform model supports capital-efficient scaling of telemedicine services. Intellectual property holdings in cannabis-related patents may offer future licensing opportunities. Completion of FINRA-notified blockchain-linked security distributions positions the company among early adopters in regulated digital asset offerings.

The company operates in a highly regulated environment with telemedicine and medical cannabis services subject to evolving federal and state laws, which could increase compliance costs or restrict operations. The company depends heavily on telemedicine revenue from a niche market, with competition from larger, better-resourced telemedicine providers. Reliance on independent third-party physicians introduces operational risks. The company reported a net loss of $2.46 million for fiscal 2025, indicating ongoing profitability challenges. Digital asset initiatives are exploratory and ancillary, potentially exposing the company to market and regulatory uncertainties. Limited financial disclosure on market capitalization and shares outstanding reduces transparency for investors.

Dogecoin Cash, Inc.'s moat is based on its specialized telemedicine platform for medical cannabis evaluations, leveraging proprietary technology and an asset-light model that enables scalable operations without physical clinics. The company holds certain cannabis-related intellectual property patents, which may provide some competitive differentiation. Its network of licensed independent physicians and compliance with state telemedicine regulations support its operational model. However, competition from larger telemedicine providers with greater resources and physician networks presents challenges. The company's digital asset initiatives through subsidiaries add a niche strategic dimension but are ancillary to its core telemedicine revenue.

• Regulatory Risks: Changes in state or federal laws governing telemedicine, medical cannabis evaluations, or physician licensing could adversely affect the company’s ability to operate or increase compliance costs.
• Competitive Risks: The company faces competition from larger telemedicine platforms with greater financial resources, larger physician networks, and more extensive technology infrastructure.
• Operational Risks: Dependence on independent third-party physicians to provide medical evaluations introduces risks related to service quality and regulatory compliance.
• Financial Risks: The company reported net losses and may require additional capital to sustain and expand operations, which could dilute existing shareholders or increase financial risk.

• Dogecoin Cash, Inc. was incorporated in Nevada in November 2004 and was formerly known as Cannabis Sativa, Inc. and Ultra Sun Corporation.
• The company operates primarily through its majority-owned subsidiary PrestoCorp, Inc., which does business as PrestoDoctor, a telemedicine platform connecting patients with licensed physicians for medical cannabis evaluations via secure video consultations in jurisdictions where permitted by state law.
• The company provides the technology platform and administrative support for telemedicine consultations; physicians are independent and responsible for their medical services.
• Substantially all revenue is generated from telemedicine consultation services facilitated through the PrestoDoctor platform.
• The company operates an asset-light platform model, facilitating telemedicine services through digital infrastructure without owning physical clinics or healthcare facilities.
• The company is not affiliated with or endorses the Dogecoin cryptocurrency and does not issue or sponsor any cryptocurrency.
• The company maintains several subsidiaries: operating (PrestoCorp, Inc.), strategic and technology (Dogecoin Treasury, Inc., DogeSPAC LLC, Meme Coins, Inc.), and others including Kubby Patent and Licenses, LLC (cannabis-related intellectual property) and Eden Holdings LLC (trademark holdings).
• The company holds cannabis-related intellectual property including a patent for the Ecuadorian Sativa cannabis strain and a patent for a cannabinoid-containing lozenge delivery system for treating hypertension.
• The company’s telemedicine platform operates in compliance with applicable federal and state laws, including physician licensing and telemedicine regulations, and HIPAA privacy standards.
• The company’s telemedicine services are subject to regulatory risks including changes in telemedicine laws, medical cannabis program regulations, and physician licensing requirements.
• The company competes with other telemedicine and healthcare technology providers, many of which have greater resources and larger physician networks.
• The company’s recent financial snapshot as of December 31, 2025, shows cash and equivalents of $29,553, current assets of $944,863, current liabilities of $840,095, a current ratio of 1.12, and a cash ratio of 0.04.
• For the fiscal year ended December 31, 2025, the company reported revenues of $738,907 and a net loss of $2,462,690.
• The company’s diluted EPS was -$0.02 for the fiscal year ended December 31, 2023.
• The company’s digital asset initiatives are conducted through subsidiaries including Dogecoin Treasury, Inc., DogeSPAC LLC, and Meme Coins, Inc., which support digital asset acquisition, investment, and treasury management.
• Meme Coins Inc., a controlled subsidiary, acquired 2 billion and later 4 billion Dogecoin Cash (DOG) tokens from Tipestry, Inc. through definitive agreements in 2025.
• The company announced a special distribution of DogeCoin Cash units to shareholders in January 2026, subject to FINRA clearance.
• PrestoDoctor has expanded telehealth cannabis evaluations to 19 states, including recent expansions into Connecticut and Michigan.
• PrestoDoctor accepts cryptocurrency payments, including Dogecoin, for its telemedicine services.
• The company’s corporate strategy focuses on expanding the telemedicine platform while maintaining a capital-efficient operating structure.
• The company maintains principal executive offices in Mesquite, Nevada, and operational office space in New York, both under rental arrangements.
• The company is not currently a party to any material legal proceedings.